Medically reviewed by Prof. Ralf Herwig, Urology, German Medical Center.
Prostate cancer screening is a personal decision based on age, family history, inherited risk and overall health. Movember is a useful reminder to have that conversation, but it is not a reason for every man to book the same tests. Screening usually starts with a discussion about the prostate-specific antigen (PSA) blood test, including what it can detect and what it cannot. European Association of Urology guidance supports an informed, risk-based approach.
At what age should the conversation start?
Different professional organisations use different starting ages. The European Association of Urology recommends considering early PSA testing in well-informed men from age 50, from 45 for men of African descent or with a family history of prostate cancer, and from 40 for men carrying a BRCA2 mutation. These are discussion points, not automatic testing instructions for every person.
Your clinician also considers your health, likely life expectancy and previous results. Someone with major health problems may face more harm than benefit from finding a slow-growing cancer. The interval between tests should also be personalised rather than assumed to be annual.
For a consultation in Dubai, bring the ages at which close relatives were diagnosed, not just a general statement that cancer “runs in the family”. Previous PSA reports are more useful than remembering that the last result was “normal”.
What does a PSA test actually show?
PSA is produced by the prostate, including by non-cancerous tissue. A raised result does not establish a cancer diagnosis: an enlarged prostate, inflammation and other factors can raise it. Conversely, a reassuring result cannot completely exclude cancer.
An unexpected result may lead to repeat testing, assessment of risk, MRI or a biopsy, depending on the circumstances. Tell the clinician about urinary infections, recent procedures and medicines such as finasteride, which can affect interpretation. Follow the testing service’s preparation instructions. The National Cancer Institute’s PSA guide explains these limitations and follow-up steps.
Why discuss the downsides of screening?
Screening can find clinically important cancer before symptoms appear. It can also find cancers that would never have caused problems during a person’s lifetime. This is called overdiagnosis. Further investigations may cause anxiety, while biopsy and treatment can carry complications.
The relevant question is therefore broader than “Can I have a PSA test?” Ask: “Given my risk, what might testing change, and what would we do with an uncertain result?” Agreeing on a follow-up plan before testing helps put the result in context.
Symptoms need assessment at any age
Screening applies to people without symptoms. Difficulty passing urine, visible blood in urine or persistent urinary changes require a clinical assessment rather than waiting for a screening birthday. These symptoms have several possible causes and do not, by themselves, mean prostate cancer. Early prostate cancer may cause no symptoms. EAU diagnostic guidance
A practical appointment checklist
Before your visit, write down:
- Your main question: routine risk assessment, a new symptom or an earlier abnormal result.
- Relevant family history and any known inherited cancer-related mutation.
- Dates and results of previous PSA tests, scans or biopsies.
- All prescribed medicines and supplements.
- What you would want to understand before agreeing to further investigations.
Ask how and when results will be communicated and who will arrange any follow-up. Leaving with a clear next step is more useful than collecting a number without an explanation.
Understand the difference between screening and diagnosis
A screening appointment begins with risk rather than an assumption that something is wrong. A diagnostic appointment begins with a symptom, examination finding or earlier result that needs explaining. The same blood test can appear in both pathways, but its purpose and the next steps are different. The NCI screening overview makes this distinction clear.
This is why a friend’s testing schedule may not be suitable for you. Your friend may be having follow-up for an earlier raised result, monitoring after treatment, or screening because of a particular family history. Asking for the same tests without that context can create confusion. At booking, say whether you are seeking preventive advice or assessment of a change you have noticed.
The distinction also helps when reviewing a health-check package. A package can make tests convenient, but convenience does not answer whether a particular test is useful. Before paying, ask whether a clinician will review your risk, explain the possible consequences of testing and arrange follow-up. A useful screening service includes the conversation before the sample and interpretation after the result.
How do family history and inherited risk affect the discussion?
Family history is more informative when it includes the relative, cancer type and age at diagnosis. A father diagnosed late in life and several relatives diagnosed at younger ages are not identical histories. The American Cancer Society recommends earlier screening discussions for higher-risk groups, including men with an affected close relative diagnosed before age 65 and those with multiple early-affected close relatives.
You do not need a complete family tree to attend. Start with what you know and clearly identify uncertainty. “My father had prostate surgery, but I do not know whether it was cancer” is more useful than assuming every prostate operation was cancer treatment. If records can be obtained, ask the relative’s permission rather than guessing from family recollections.
A known inherited mutation is different from a family history alone. Bring the actual genetic report if you have one. The clinician can advise whether the result is relevant to prostate risk and whether specialist genetic advice is appropriate. Do not purchase a genetic test solely because a commercial advertisement presents it as part of a routine screening bundle.
What might happen during the first appointment?
The clinician will usually begin with your medical and family history, medicines and any urinary symptoms. Depending on the reason for attending, assessment may involve an examination, urine testing or other investigations. The NIDDK guide to prostate tests explains that different tests answer different questions about prostate size, urinary function and possible cancer.
If an examination is suggested, ask what it involves and why it is useful. You can discuss concerns, request an explanation before proceeding and ask about a chaperone. An examination should form part of a reasoned assessment, rather than being presented as a definitive guarantee that cancer is absent.
At the end of the consultation, try to state the plan back in your own words. For example: “We are checking my risk first; if I choose PSA testing, we will review the result together before deciding whether anything else is needed.” This simple recap can uncover misunderstandings about whether the appointment is preventive, diagnostic or follow-up.
How should you think about an uncertain result?
An uncertain result can feel like a demand to make an immediate decision. A more useful response is to ask what uncertainty remains. Is the concern a temporary change, a result that differs from earlier measurements, or a pattern that needs specialist investigation? The clinician should explain which question the next step is intended to answer.
Screening can produce false-positive results, where an abnormal finding does not ultimately mean cancer, and false-negative results, where screening fails to identify a cancer that is present. These are among the limitations described in the NCI screening guide. They are reasons to interpret tests carefully, not reasons to ignore follow-up.
Avoid comparing your number with a stranger’s result on a forum. Age, medicines, previous results and the reason for testing can change the interpretation. Keep a copy of the report, note the date and arrange the review that was agreed. If you have not received the result by the expected time, contact the service rather than assuming silence means everything was normal.
Which questions help before further investigations?
If additional testing is recommended, focus on what it adds to the decision. You might ask: “What are we trying to rule in or rule out?”, “What happens if the result is reassuring?”, and “What would make you recommend a biopsy?” These questions turn a sequence of tests into an understandable pathway.
Also ask about practical consequences. Will you need preparation, transport, time away from work or changes to medicines? Who will explain the result, and how quickly should that happen? If care is split between providers, clarify who is responsible for arranging the next appointment. Written instructions are particularly helpful when you are organising care around travel or work in Dubai.
A second opinion can be useful when you remain unsure about a non-urgent decision. Share the original reports and the question you want reviewed. Repeating the entire pathway without explaining earlier findings can make care less coherent. The aim is to understand the reasoning and available choices, not to collect a preferred answer.
Make a decision that reflects your preferences
Two people with similar medical risk may value the trade-offs differently. One may place a high value on knowing as much as possible; another may be particularly concerned about investigations that could identify a problem unlikely to affect their life. Neither preference removes the need for accurate information. Shared decision-making means combining the evidence with what matters to you.
Try to identify the specific concern behind your preference. Are you worried because a relative had advanced cancer? Do you fear biopsy complications? Are you unsure how you would cope with monitoring? Naming the concern allows the clinician to address it directly instead of assuming that agreement to a blood test means agreement to every possible later intervention.
You can also ask what would prompt reconsideration if you decide not to test now. A decision can include a future review rather than being permanent. Keep the agreed plan with your other health records so a later clinician can understand what was discussed and why.
Read screening statistics with the right denominator
When someone describes a screening benefit as a percentage, ask what the number refers to. Is it the chance of detecting a cancer, the chance of avoiding a death from that cancer, or the chance of needing another investigation? These are different outcomes. A higher detection rate alone does not tell you the full balance of benefit and harm.
Ask for absolute numbers over a stated period when they are available. For example, a clinician might explain an outcome in terms of how many people out of a thousand experience it over several years. That format can be easier to understand than a relative percentage without a starting risk. Do not assume that a figure from one age group applies unchanged to another.
It is also worth asking whether a statistic refers to screening, diagnosis or treatment. An excellent result after treatment does not, by itself, answer whether screening is worthwhile for everyone. Similarly, a test’s ability to detect an abnormality is not the same as a guarantee that acting on the result improves a person’s life.
If a number is unclear, ask the clinician to explain it in ordinary language. You should not need to become a statistician to participate in the decision. The purpose of discussing evidence is to make your choice more informed, not to overwhelm you with figures.
A useful final check is to ask: “Does this information change your recommendation for me, and why?” That brings the discussion back from population-level evidence to your circumstances. Keep the explanation with your screening plan so that future reviews can build on the same reasoning rather than starting again with an isolated number.
Common questions about Movember screening
Should I test every November? The awareness month can remind you to review your health, but the appropriate interval comes from your individual plan. Do not replace that plan with an annual campaign calendar. If you already receive prostate follow-up, ask your usual clinician whether anything needs updating.
Does a urinary problem mean I have cancer? No. Symptoms need assessment because several conditions can cause them. Non-cancerous enlargement is a separate condition from prostate cancer; the NCI guide to prostate changes explains why the cause should be established rather than inferred from symptoms alone.
Can I have a consultation without agreeing to a test? Yes. A discussion is a legitimate first step. You can ask for an explanation of benefit, harm and alternatives before deciding. Tell the clinic that you want a screening-risk discussion so enough time can be allocated to your questions.
What is the most useful thing to do this month? Organise your previous results, clarify relevant family history and book a discussion if you are unsure about your risk. A documented plan that you understand is more useful than taking a test simply because the month has changed.
Discuss prostate health at German Medical Center
GMC’s urology service can be a starting point for a prostate-health discussion. Review the specialist directory or contact German Medical Center to request an appointment. Bring earlier records so the clinician can assess the full picture.
If screening leads to further questions, GMC also covers prostate cancer assessment and care and enlarged prostate (BPH) treatment. For more reading, see what PSA results mean and what happens next, enlarged prostate vs prostate cancer and essential screenings for men.
This article provides general health information and does not replace an individual medical assessment.
